Effects of microwave ablation on serum Golgi protein 73 in patients with primary liver cancer

Figure 1 Disease-free survival rates of the patients with primary liver cancer after treatment with microwave ablation. The disease-free survival (DFS) rates were analyzed at 6, 12, 18, 24, 30, and 36 mo after microwave ablation (MWA) for primary liver cancer in the patients. The 1-, 2-, and 3-year DFS rates after MWA were 74.67%, 59.33%, and 54.00%, respectively. DFS: Disease-free survival.

Figure 2 Effects of microwave ablation treatment on the serum alpha-fetoprotein levels in patients with primary liver cancer. The serum alpha-fetoprotein (AFP) levels were examined in the primary liver cancer patients before microwave ablation (MWA) treatment and at different time points after the treatment. The average serum AFP level was 110.4 mg/L before MWA treatment (pre-MWA), decreased sharply to 37.61 mg/L at 1 wk after MWA treatment, continued to decrease, returned to the normal range at 12 wk after MWA, and remained stable thereafter during follow-up in those cases without recurrence. For the recurrent cases with primary liver cancer, however, the serum AFP levels started to increase at 12 wk following the MWA treatment. AFP: Alpha-fetoprotein.

Figure 3 Comparison of serum Golgi protein 73 levels in the primary liver cancer patients with vs without liver cirrhosis. The serum Golgi protein 73 levels were examined in the primary liver cancer patients with compensated liver cirrhosis (n = 115) vs those without liver cirrhosis (n = 35). P < 0.05. GP73: Golgi protein 73.

Figure 4 Effects of microwave ablation treatment on serum Golgi protein 73 levels in the enrolled patients with primary liver cancer. The serum Golgi protein 73 (GP73) levels were examined in the primary liver cancer patients before and after microwave ablation (MWA) treatment. The serum GP73 levels were increased 1 and 2 wk after MWA. The serum GP73 levels reached the peak at 2 wk after MWA, then progressively decreased, and returned to the pretreatment levels 12 and 24 wk following the MWA treatment. GP73: Golgi protein 73.